Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced the approval of inducement grants for 24 new employees by its Compensation Committee on December 14, 2021. The grants, totaling up to 87,000 restricted stock units, are meant to incentivize employment and are outside the company’s stockholder-approved equity incentive plans. These units will vest annually over four years, reflecting the company's commitment to attracting talent in its mission to develop innovative RNA interference therapies for intractable diseases.

Positive

• Inducement grants approved for 24 new employees strengthen talent acquisition.
• Total of 87,000 restricted stock units granted, enhancing employee retention.

Negative

• None.

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 14, 2021, the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 24 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 87,000 restricted stock units. The grants are outside the Company’s stockholder-approved equity incentive plans and vest annually over four years.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Source: Arrowhead Pharmaceuticals, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211217005630/en/

Arrowhead Pharmaceuticals, Inc.

Vince Anzalone, CFA

626-304-3400

ir@arrowheadpharma.com

Investors:

LifeSci Advisors, LLC

Brian Ritchie

212-915-2578

britchie@lifesciadvisors.com

www.lifesciadvisors.com

Media:

LifeSci Communications, LLC

Josephine Belluardo, Ph.D.

646-751-4361

jo@lifescicomms.com

www.lifescicommunications.com

Source: Arrowhead Pharmaceuticals, Inc.

FAQ

What is the purpose of the inducement grants approved by Arrowhead Pharmaceuticals?

The inducement grants are meant to incentivize 24 new employees to join the company.

What is the total number of restricted stock units granted by Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals approved grants totaling up to 87,000 restricted stock units.

When were the inducement grants for Arrowhead Pharmaceuticals approved?

The inducement grants were approved on December 14, 2021.

How will the restricted stock units vest for Arrowhead Pharmaceuticals employees?

The restricted stock units will vest annually over four years.

Are the inducement grants part of Arrowhead Pharmaceuticals' stockholder-approved plans?

No, the grants are outside the company’s stockholder-approved equity incentive plans.